You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Moodys
Medtronic
Harvard Business School
Mallinckrodt

Last Updated: September 21, 2020

DrugPatentWatch Database Preview

Claims for Patent: 8,980,248

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,980,248
Title:Injectable polymer composition for use as a cell delivery vehicle
Abstract: This invention provides a polymer composition comprising at least one thermal gelling polymer and at least one anionic polymer for cell delivery applications. These injectable polymer compositions are shear-thinning, thixotropic and resorbable. More specifically there is described a hyaluronan (HA) and methylcellulose (MC) based thermogelling cell delivery system (HAMC) that promotes cell survival both in vitro and in vivo. Importantly, HAMC (relative to media alone) enhances survival of transplanted stem/progenitor cells in the injured CNS. HAMC provides a minimally-invasive cell delivery strategy where the microenvironment can be further defined and the differentiation and regenerative capacity further explored. This hydrogel system has applications for minimally-invasive cell delivery to other tissues/organs in the body as well.
Inventor(s): Shoichet; Molly Sandra (Toronto, CA), Zahir; Tasneem (Mississauga, CA), Ballios; Brian (Mississauga, CA), Van der Kooy; Derek (Toronto, CA), Cooke; Michael (Toronto, CA)
Assignee: The Governing Council of the University of Toronto (Toronto, Ontario, CA)
Application Number:13/516,846
Patent Claims:1. An injectable cell delivery composition comprising as a cell delivery vehicle a polymer composition comprising: i) at least one thermal gelling polymer; ii) at least one anionic gelling polymer; and iii) a water-based carrier, wherein the polymer composition is injectable due to its shear thinning properties, the viscosity and network density of said polymer composition being effective to promote cell survival in vivo and in vitro and to maintain a distribution of cells after injection; and at least one cell type for delivery selected from the group consisting of mammalian cells, stem cells, precursor and progenitor cell populations isolated from the adult neural subventricular zone, hippocampal subgranular zone, spinal cord, skin-derived precursors or adult retinal ciliary epithelium and their undifferentiated and differentiated progeny; embryonic stem cells and their undifferentiated and differentiated progeny; epiblast stem cells and their undifferentiated and differentiated progeny; primitive and definitive neural stem cells and their undifferentiated and differentiated progeny; induced pluripotent stem cells and their undifferentiated and differentiated progeny; mesenchymal stem cells and their undifferentiated and differentiated progeny; bone-marrow derived stem cells and their undifferentiated and differentiated progeny; hematopoietic stem cells and their undifferentiated and differentiated progeny; umbilical cord derived stem/progenitor cells and their undifferentiated and differentiated progeny; neural precursor cells of the forebrain, midbrain, hindbrain, spinal cord, neural crest, and retinal precursors isolated from developing tissue and their undifferentiated and differentiated progeny; and at least one factor capable of stimulating endogenous stem cells when present.

2. The injectable cell delivery composition as claimed in claim 1, wherein the thermal gelling polymer has a molecular weight between about 2,000 Da and about 1,000,000 Da and the anionic gelling polymer has a molecular weight between about 100,000 and about 7,000,000 Da and the ratio of the gelling polymer to the anionic polymer is at least about 0.1:1 to about 20:1 w/w.

3. The injectable cell delivery composition as claimed in claim 2, wherein the thermal gelling polymer is an inverse thermal gelling polymer selected from methylcellulose, a chitosan and beta-glycerophosphate solution, collagen, tri-block copolymer of poly(ethylene glycol)-poly(lactic-co-glycolic acid)-poly(ethylene glycol), tri-block copolymer of poly(propylene glycol)-poly(ethylene glycol)-poly(propylene glycol), poly(N-isopropyl acrylamide), agarose, copolymers of poly-N-isopropylacrylamide, polysaccharides and mixtures thereof; and the anionic gelling polymer is selected from: hyaluronic acid, derivatives of hyaluronic acid, alginate, derivatives of alginate, carboxymethylcellulose, and mixtures thereof.

4. The injectable cell delivery composition as claimed in claim 1, wherein the thermal gelling polymer is methylcellulose (MC) and the anionic gelling polymer is hyaluronic acid (HA).

5. The injectable cell delivery composition as claimed in claim 1, wherein the polymer composition is comprised of about 0.5% w/w methylcellulose and about 0.5% w/w hyaluronic acid.

6. The injectable cell delivery composition as claimed in claim 1, wherein the water-based carrier is selected from the group comprising: water, salt solutions, artificial cerebrospinal fluid, media, and buffered solutions.

7. The injectable cell delivery composition as claimed in claim 5, wherein the water-based carrier is selected from the group comprising: water, salt solutions, artificial cerebrospinal fluid, media, and buffered solutions.

8. The injectable cell delivery composition as claimed in claim 1, in a form for injection selected from the group consisting of subcutaneous, intramuscular and intravenous for delivery to a cavity in a patient creating surgically for therapeutic intervention or resulting from disease or injury.

9. The injectable cell delivery composition as claimed in claim 7, in a form for injection selected from the group consisting of subcutaneous, intramuscular and intravenous for delivery to a cavity in a patient creating surgically for therapeutic intervention or resulting from disease or injury.

10. The injectable cell delivery composition as claimed in claim 1, wherein the cells are delivered as spheres, aggregates or single cell suspensions.

11. The injectable cell delivery composition as claimed in claim 9, wherein the cells are delivered as spheres, aggregates or single cell suspensions.

12. The injectable cell delivery composition as claimed in claim 1, wherein at least one pharmaceutical agent is also present selected from the group comprising anesthetics for use in caudal, epidural, inhalation, injectable, retrobulbar, and spinal applications; analgesics, selected from the group comprising acetaminophen, ibuprofen, fluriprofen, ketoprofen, voltaren, phenacetin and salicylamide; anti-inflammatories selected from the group comprising naproxen and indomethacin; antihistamines, selected from the group comprising chlopheniramine maleate, phenindamine tartrate, pyrilamine maleate, doxylamine succinate, henyltoloxamine citrate, diphenhydramine hydrochloride, promethazine, brompheniramine maleate, dexbrompheniramine maleate, clemastine fumarate and triprolidine; antitussives selected from the group comprising dextromethorphan hydrobromide and guaifenesin; expectorants; decongestants, selected from the group comprising phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride, and ephedrine; antibiotics selected from the group comprising amebicides, broad and medium spectrum, fungal medications, monobactams and viral agents; bronchodilators selected from the group comprising theophylline, albuterol and terbutaline; cardiovascular preparations selected from the group comprising diltiazem, propranolol, nifedepine, clonidine, alpha adrenoceptor agonists, alpha receptor blocking agents, alpha and beta receptor blocking agents, antiotensin converting enzyme inhibitors, beta blocking agents, calcium channel blockers, and cardiac glycosides; central nervous system drugs selected from the group comprising thioridazine, diazepam, meclizine, ergoloid mesylates, chlorpromazine, carbidopa and levodopa; metal salts selected from the group comprising potassium chloride and lithium carbonate; minerals selected from the group consisting of iron, chromium, molybdenum and potassium; immunomodulators; immunosuppressives selected from the group comprising minocycline, cyclosporine A; thyroid preparations selected from the group comprising synthetic thyroid hormone, and thyroxine sodium; peptide and glycoprotein hormones and analogues selected from the group comprising human chorionic gonadotrophin (HCG), corticotrophin, human growth hormone (HGH.about.Somatotrophin) and erythropoietin (EPO); steroids and hormones selected from the group comprising ACTH, anabolics, androgen and estrogen combinations, androgens, corticoids and analgesics, estrogens, glucocorticoid, gonadotropin, gonadotropin releasing, hypocalcemic, menotropins, parathyroid, progesterone, progestogen, progestogen and estrogen combinations, somatostatin-like compounds, urofollitropin, vasopressin, methyl prednisolone, and GM1 ganglioside; small molecules, including taurine, retinoic acid, sodium butyrate, cAMP, dbcAMP; vitamins selected from the group comprising water-soluble vitamins and veterinary formulations; growth factors, proliferative factors, differentiation factors and morphogens selected from the group comprising EGF, FGF2, EPO, PDGF-AA, BDNF, GDNF, SHH, IFN-.gamma. and neurotrophins; peptides, peptide mimetics and other protein preparations; anti-angiogenics selected from the group comprising, but not limited to, ranibizumab, bevacizumab, and pegaptanib; DNA; and, small interfering RNAs; and when required a pharmaceutically acceptable carrier or preservative; and at least one factor capable of stimulating endogenous stem cells is present.

13. The injectable cell delivery composition as claimed in claim 12, wherein the at least one pharmaceutical agent is covalently bonded to at least one of the thermal gelling polymer and the anionic gelling polymer.

14. The injectable cell delivery composition as claimed in claim 12, wherein the at least one pharmaceutical agent is encapsulated in a micron-sized particle or nanoparticle selected from microspheres, micron-sized rods, nanospheres, nanorods and liposomes; and the micron-sized particles that incorporate the pharmaceutical agents are dispersed in the polymer along with the cells prior to injection to ensure an even distribution of cells and microspheres.

15. The injectable cell delivery composition as claimed in claim 4, wherein the ratio of MC to HA is about 0.1:1 to about 5:1 w/w.

16. The injectable cell delivery composition as claimed in claim 15, wherein the concentration of MC is from 0.5 wt. % to 1.0 wt. % and the concentration of HA is from 0.5 wt. % to 1.0 wt. %.

Summary for Patent:   Start Trial

PCT Information
PCT FiledDecember 17, 2010PCT Application Number:PCT/CA2010/002060
PCT Publication Date:June 23, 2011PCT Publication Number:WO2011/072399

Details for Patent 8,980,248

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Ferring BRAVELLE urofollitropin INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 021289 001 2002-05-06   Start Trial The Governing Council of the University of Toronto (Toronto, Ontario, CA) 2029-12-18 DISCN search
Ferring BRAVELLE urofollitropin INJECTABLE; SUBCUTANEOUS 021484 001 2002-12-19   Start Trial The Governing Council of the University of Toronto (Toronto, Ontario, CA) 2029-12-18 RX search
Ferring MENOPUR menotropins (fsh;lh) INJECTABLE;SUBCUTANEOUS 021663 001 2006-03-20   Start Trial The Governing Council of the University of Toronto (Toronto, Ontario, CA) 2029-12-18 RX search
Ferring Pharmaceuticals Inc. MENOPUR menotropins KIT 021663 1 2004-10-29   Start Trial The Governing Council of the University of Toronto (Toronto, Ontario, CA) 2029-12-18 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Merck
Express Scripts
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.